J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb
J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb
$200.00
Scrip reports from Day 2 of the 2019 J.P. Morgan Healthcare Conference, bringing you the highlights to come out of the San Francisco meeting. Read the most important news from Day 2, including the latest from Biogen, updates on GSK’s oncology efforts, deal developments for bluebird and Lilly, and more.
Author: Mandy Jackson
Publisher: Scrip
- Description
Day 2 of San Francisco’s 2019 J.P. Morgan Healthcare Conference brought with it some notable announcements, and Scrip was there to report on the day’s most important news. Discover all of the essential developments from Day 2, including updates on Amgen deal making, new competition from Biohaven for Allergen’s stronghold on the migraine headache space, highlights from Commissioner Scott Gottlieb’s keynote address, and updates from Roche, GSK, and more. Tap into the vital news from Day 2 of the J.P. Morgan Healthcare Conference, as delivered by the experts from Scrip.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room 
Sign up to the